Caris Life Sciences Partners with Everlywell to Launch Caris' Forthcoming MCED Assay, Caris Detect

{
  "signal_id": "3be5facf-be43-46a2-9425-0f669437b10a",
  "signal_type": "news",
  "signal_subtype": "partners_with",
  "detected_at": "2026-01-12T13:00:00+00:00",
  "company": {
    "name": "Caris Life Sciences",
    "domain": "carislifesciences.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/caris-life-sciences-partners-with-everlywell-to-launch-caris-forthcoming-mced-assay-caris-detect-302657803.html",
    "title": "Caris Life Sciences Partners with Everlywell to Launch Caris' Forthcoming MCED Assay, Caris Detect",
    "excerpt": "Caris Life Sciences partners with Everlywell to launch Caris' forthcoming MCED assay, Caris Detect.\n\nNews provided by.\n\nIRVING, Texas, Jan. 12, 2026 /PRNewswire/ - Caris Life Sciences(R)(NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced a partnership with Everlywell, a digital health company pioneering the next generation of biomarker intelligence, combining AI-powered technology with human insight to deliver personalized, actionable health answers.\n\nCaris and Everlywell are partnering to launch Caris Detect(TM), Caris' forthcoming Multi-Cancer Early Detection (MCED) blood-based screening assay, through Everlywell's platform. Caris Detect utilizes comprehensive whole genome sequencing (WGS) technology to identify multiple cancer types by analyzing molecular signals circulating in the bloodstream.\n\n\"Caris Life Sciences is proud to partner with Everlywell to expand access to Caris Detect, Caris' revolutionary MCED assay driven by WGS technology,\" said Caris President David Spetzler, MS, PhD, MBA. \"By combining our advanced precision medicine technologies with Everlywell's consumer-focused platform, we're creating a powerful new pathway for people to detect cancer at its earliest and most treatable stages, before it can spread, ultimately supporting better outcomes for patients.\"\n\n\"Our partnership with...",
    "summary": "Caris Life Sciences, Ltd. partnered with Everly Health, Inc. on Jan 12th '26.",
    "category": "partners_with",
    "found_at": "2026-01-12T13:00:00Z",
    "location": "Texas, United States",
    "planning": false,
    "image_url": "https://mma.prnewswire.com/media/830740/Caris_Life_Sciences_Logo.jpg?p=facebook",
    "confidence": 0.4164,
    "published_at": "2026-01-12T13:00:00Z",
    "location_data": [
      {
        "state": "Texas",
        "country": "United States",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-01-12",
    "article_sentence": "IRVING, Texas, Jan. 12, 2026 /PRNewswire/ - Caris Life Sciences(R)(NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced a partnership with Everlywell, a digital health company pioneering the next generation of biomarker intelligence, combining AI-powered technology with human insight to deliver personalized, actionable health answers."
  }
}

curl https://signals.autobound.ai/v1/signals/3be5facf-be43-46a2-9425-0f669437b10a \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"carislifesciences.com","limit":20}'